RecruitingNCT07075861

The ARTEMIS Data Collection Study

JenaValve Trilogy for Patients With Pure Native Aortic Valve Rigurgitation: the ARTEMIS Data Collection Study


Sponsor

IRCCS Policlinico S. Donato

Enrollment

75 participants

Start Date

Aug 10, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

To observe the safety and effectiveness of the JenaValve Trilogy™ Heart Valve System for transcatheter aortic valve replacement (TAVR) in subjects with evere native aortic regurgitation (AR) who are indicated for TAVR Data collection


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Considered at high or prohibitive risk for surgical aortic valve replacement by the Heart Team
  • years of age or older
  • Suitable anatomy according to the IFU
  • Absence of significant disease of the ascending aorta, including ascending aortic aneurysm (defined as maximal luminal diameter of 50mm or greater) or atheroma (especially if thick \[\>5mm\], protruding or ulcerated)

Exclusion Criteria1

  • The JenaValve Trilogy Heart Valve System is contraindicated for use in patients who have known hypersensitivity or contraindication to Nitinol (titanium and/or nickel), an anti-coagulation/anti-platelet regimen or contrast medium that cannot be managed with premedication, or who have active bacterial endocarditis or other active infections.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

IRCCS Policlinico San Donato

San Donato Milanese, Milano, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07075861


Related Trials